⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NSRX News
Nasus Pharma Ltd.
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
globenewswire.com
NSRX
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
globenewswire.com
NSRX
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
globenewswire.com
NSRX